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Abstract: Treatment of advanced, recurrent or persistent cervical cancer includes radiotherapy 
and chemotherapy. Radiation has been the primary treatment modality for locoregionally 
advanced cervical cancer. Concomitant systemic cisplatin chemotherapy and radiation have 
shown high response rates with improvements in durable remissions and overall survival. 
Cisplatin has been the standard medication for the treatment of advanced cervical cancer. 
Combinations with other chemotherapeutic agents have been the subject of clinical trials with 
varying results. The toxicity of combination chemotherapy and tolerability of patients are 
other factors that should be considered in the management of patients with advanced disease. 
Recently topotecan, in combination with cisplatin, achieved increased response and overall 
survival rates without further compromising the patients’ quality of life. This review focuses 
on the mechanism of action and toxicities of topotecan, as well as its role as a radio-sensitizer 
and chemotherapeutic agent in the management of advanced, recurrent, or persistent cervical 
cancer. Other combination modalities and dosages are also discussed.
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Introduction
Invasive carcinoma of the cervix is the second cause of death in women worldwide, 
with an estimated 510,000 newly diagnosed cases and 280,000 deaths each year 
(Salslow et al 2007). In developing countries, cervical cancer is often the most 
common cancer in women. The American Cancer Society (ACS) Cancer Facts and 
Figures (2007) reported that an estimated 11,150 cases of invasive cervical cancer 
will be diagnosed in the United States, and an estimated 3,670 women will die from 
this disease.
Although the incidence of cervical cancer has declined markedly since the intro-
duction of screening tests, the overall mortality rates have not changed in the past 
25 years (Fiorica 2003). The American Cancer Society Guideline for the Early Detec-
tion of Cervical Cancer was reviewed and updated in 2002; for the ﬁ  rst time, those 
recommendations incorporated options including liquid-based cytology and human 
papilloma virus (HPV) DNA testing (Salslow et al 2007).
The prognosis of advanced cervical cancer is discouraging. Recurrent, persistent 
or advanced cervical cancer responds poorly to current treatment modalities. Five-
year survival rates have been approximately 41%–51% and 8%–17% for patients with 
regional and distant disease, respectively (Tiersten et al 2004). Recent addition of 
chemotherapy to radiation treatment has increased overall survival for patients with 
regional disease to greater than 60% (Whitney et al 1999). Four randomized trials of 
chemo-radiation demonstrated positive results prompting a National Cancer Institute 
(NCI) clinical announcement for change in standard of care (Keys et al 1999; Morris 
et al 1999; Rose et al 1999; Peters et al 2000).Therapeutics and Clinical Risk Management 2008:4(1) 214
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At the present time, there is no effective treatment for 
metastatic disease and recurrences. Studies of cisplatin 
chemotherapy in cervical cancer demonstrate response rates 
of approximately 20%–30% with a median survival of 6–7 
months. For recurrent or metastatic disease, chemotherapy 
is palliative. Complete responses are unusual and generally 
limited to patients with lung metastasis (Berek et al 2005). 
The high mortality rate, low response rate to available treat-
ments and short survival mandates investigation into more 
effective therapies.
Various treatment protocols have been suggested to 
increase the survival of patients with cervical cancer. These 
protocols include radiotherapy and chemoradiation for loco-
regional disease, and single or combination chemotherapy 
for widely metastatic or recurrent cancer.
If recurrent disease presents in the central pelvis, then 
pelvic exenteration by experienced surgeons may yield ﬁ  ve-
year success rate of 32%–62% in the appropriate patients 
(DuPont et al 2006). Chemotherapy represents the best 
therapy for recurrent disease not curable by exenterative 
surgery. Chemotherapy is also the most reasonable option 
for patients presenting with distant metastases.
Topotecan is an effective chemotherapy agent for treat-
ment of ovarian cancer and small-cell lung cancer. It was 
approved for use in combination with cisplatin by the US 
Food and Drug Administration (FDA) in 2006 for treat-
ment of women with stage IVB, recurrent, or persistent 
carcinoma of the cervix not amenable to curative treatment 
with surgery and/or radiation therapy (Brave et al 2006). 
This article will review the role of topotecan in the treatment 
of advanced (stage IV or widely metastatic) and recurrent 
cervical cancer.
Pharmacology of topotecan
Topotecan is a semisynthetic derivative of the pentacyclic 
alkaloid, camptothecin that is isolated from the Chinese yew 
tree, Camptotheca acuminata. The family of camptothecins 
includes irinotecan, topotecan, and 9-aminocaptothecin 
(Randall-Whitis et al 2007).
Two mechanisms of action have been described for 
topotecan. The principal mechanism is inhibition of DNA 
topoisomerase I. During normal DNA replication double 
stranded DNA separates and topoisomerase I regulates the 
broken DNA strand. This break is reversible and non-lethal 
for cell, but camptothecins convert this single stranded break 
to an irreversible double stranded break (Randall-Whitis et al 
2007). This results in inhibition of RNA transcription and 
apoptotic cell death. Camptothecins exert their cytotoxic effect 
predominantly in cell in S phase because of their selective 
topoisomerase I poisoning effect (Ling et al 2001).
The second, recently discovered mechanism of action 
of topotecan is inhibition of the hypoxia-inducible factor 
(HIF). This mechanism is of particular interest in cervical 
cancer, because tumor tends to be either bulky or present in 
radiated ﬁ  elds, which often results in tumor hypoxia. HIF is 
a transcriptional factor, which induces expression of genes 
encoding proteins enabling cell survival in hypoxic condi-
tion. These proteins induce glycolytic enzymes required for 
anaerobic metabolism and growth factors such as vascular 
endothelial growth factor that stimulates tumor angiogen-
esis, as well as erythropoietin that increases the potential 
of oxygen delivery to the tumor (Belozerov VE. Van Meir 
EG. 2005).
Topotecan as a single agent
in cervical cancer
Topotecan, in preclinical studies, demonstrated signiﬁ  cant in 
vitro activity of solid tumor explants derived from colorectal, 
breast, ovarian, renal cell, non-small cell lung cancer, and 
gastrointestinal sources. Notable activity was also demon-
strated in vivo in a wide range of animal tumor models.
Rowinsky et al (1997) reviewed phase 1 clinical studies 
with topotecan with as many as 14 different dosing schedules. 
Complete and partial responses were demonstrated in patients 
with a wide variety of solid tumors including squamous cell 
carcinoma. Myelosuppression was the major dose-limiting 
toxicity across all schedules, and non-hematologic toxicities 
were generally mild. Based on this information, there was 
substantial enthusiasm for further evaluating topotecan in a 
wide range of cancer patients in phase II studies.
Muderspach et al (2001) conducted a Gynecologic Oncol-
ogy Group (GOG) phase II multicenter study (GOG 76-U) 
in patients with advanced, recurrent or persistent squamous 
cell carcinoma of the uterine cervix. Intravenous topotecan 
was administered at 1.5 mg/m2 per day for 5 consecutive 
days every 4 weeks in patients without prior chemotherapy, 
aside from chemosensitizing agents used in conjunction with 
radiotherapy. The median progression-free interval was 2.4 
months. The median overall survival was 6.4 months. The 
overall response rate (complete and partial) was 18.6%. 
Hematological toxicity was common, with 68% of patients 
experiencing grade 4 neutropenia and 18% grade 4 throm-
bocytopenia. Grade 3–4 gastrointestinal and neurologic 
toxicities were seen in 9% and 5% of patients. However, in 
patients with prior radiation and borderline renal function, 
dose reduction of 1.25 mg/m2 is recommended. Topotecan Therapeutics and Clinical Risk Management 2008:4(1) 215
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administered at this dose and schedule demonstrates moderate 
activity with substantial hematological toxicity.
Bookman et al (2000) reported on a multicenter phase 
II study of patients with previously treated squamous cell 
carcinoma of cervix (GOG 127-F) who had received one 
prior chemotherapy regimen . Patients received topotecan 
1.5 mg/m2 daily for 5 consecutive days on a 21-day cycle. 
The overall response rate was 12.5%. Progression free inter-
val was 2.1 months and overall survival was 6.6 months. 
Topotecan had less gastrointestinal toxicity than irinotecan, 
another derivative of camptothecin with similar overall 
response rate. The single agent activity of topotecan in 
cervical carcinoma was also the subject of a report by Noda 
et al (1996) in which 4 of 22 (18%) evaluable patients 
achieved a partial tumor response.
Most clinical studies have used a 5-day regimen of short 
intravenous infusions. However, the optimal schedule has not 
yet been deﬁ  ned. Phase I/II studies have examined 24 hour 
infusions every 3 weeks versus continuous intravenous for 
21 days. These data suggested that topotecan delivered as 
a continuous intravenous infusion over 21 days as a single- 
agent therapy does not appear to offer a clinical advantage 
over conventional 5-day schedules (Hochester et al 1994; 
Van Warmerdam et al 1995; Mainwaring et al 1997).
Topotecan in combination 
chemotherapy in cervical cancer: 
cisplatin and topotecan studies
Cisplatin represents the most active single agent in palliative 
chemotherapy-appropriate cervical cancer and single agent 
topotecan has demonstrated activity in treatment of cervical 
cancer. In previous clinical trials of platinum-based thera-
pies in patients with widely metastatic or recurrent cervical 
cancer, there has often been a tradeoff between response 
rate and tolerability of treatment regimens, often with no 
differences in survival for the regimens with more severe 
toxicity proﬁ  les. GOG trial (GOG 110) compared cisplatin 
monotherapy with two cisplatin-based combination regi-
mens (cisplatin/mitolactol and cisplatin/ifosfamide). Despite 
higher response rates for the combination therapies, no sig-
niﬁ  cant differences in survival were detected; moreover, the 
cisplatin/ifosfamide group suffered signiﬁ  cant neurotoxicity 
(Omura et al 1997).
Cisplatin monotherapy has also been compared with 
cisplatin/paclitaxel in patients with recurrent or persistent 
cervical cancer (GOG Trial 169). The combination therapy 
was associated with a significantly increased response 
rate over cisplatin alone (36% vs 19%, p = 0.002) with 
no difference in median survival (9.7 vs 8.8 months). The 
cisplatin/paclitaxel group did experience higher incidence 
of grade 3–4 neutropenia (67% vs 3%) and anemia (27% 
vs 13%), and grade 1–4 neuropathy (36% vs 21%) (Moore 
et al 2004).
Topotecan and cisplatin have non-overlapping toxicities; 
therefore, a phase II trial of topotecan and cisplatin in persis-
tent or recurrent squamous and non-squamous of the cervix 
was preformed. The tolerability of the cisplatin/topotecan 
combination has been established in phase I trials (Rowinsky 
et al 1997; Bell et al 2001; Dunton et al 2002). Based on dose-
limiting hematological toxicities, the recommended doses for 
follow up in phase II studies were 0.75 to 1 mg/m2/day of 
topotecan for 5 days and 50 mg/m2 of cisplatin on day one.
A phase II trial of cisplatin and a 3-day topotecan 
regimen was studied with the hypothesis that this would 
be less bone marrow suppressive especially in previously 
irradiated patients. The overall response rate in this trial was 
28% and median overall survival of 10 months and median 
progression-free interval of 5 months (Fiorica et al 2002). 
Importantly, in this trial responses were seen in tumor in 
previously irradiated ﬁ  elds.
Long et al (2005) in GOG-0179, a randomized phase III 
trial, demonstrated a survival advantage for combination 
chemotherapy over cisplatin alone in advanced cervical 
cancer. Their regimen included cisplatin 50 mg/m2 q 21 days 
vs cisplatin 50 mg/m2 day 1 + topotecan 0.75 mg/m2 for 
3 days q21 days vs a methotroxate, vinblastin, doxorubicin 
and cisplatin (MVAC) arm. The MVAC arm was closed due 
to 4 treatment-related deaths among 63 patients and was not 
included in the ﬁ  nal analysis of the study.
Two hundred ninety-four patients enrolled onto the 
remaining regimens: 146 to cisplatin and 147 to cisplatin/
topotecan. Grade 3 to 4 hematological toxicity was more 
common with cisplatin/topotecan (see Table 1, 2). Patients 
receiving cisplatin/topotecan had statistically superior 
outcomes to those receiving Cisplatin alone, with median 
overall survival (OS) of 9.4 and 6.5 months (p = 0.017), 
median progression free survival (PFS) of 4.6 and 2.9 months 
(p = 0.014) and response rate of 27% and 13%, respectively. 
This trial demonstrated improved PFS and OS when com-
pared with single-agent therapy (Long et al 2005).
Topotecan plus cisplatin combination regimen was 
approved by the Food and Drug Administration (FDA) in 
2006, for use in recurrent, or persistent carcinoma of the 
cervix not amenable to curative treatment with surgery and/or 
radiation therapy. Brave et al (2006) reviewed the database 
supporting this approval.Therapeutics and Clinical Risk Management 2008:4(1) 216
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The GOG instituted a multi-arm trial of cisplatin in 
combination with vinorelbine, gemcitabine, paclitaxel or 
Topotecan (GOG-204). Earlier this year, the GOG interim 
analysis closed the study when data “indicated that all the 
experimental arms… were unlikely to demonstrate improved 
survival over control (cisplatin and paclitaxel)”. Unfor-
tunately, the toxicity data from the four arms will not be 
revealed until the survival data mature. Thus it is difﬁ  cult to 
conclude if one arm is superior on the basis of toxicity given 
presumably similar survival rates. Based upon phase III data, 
Topotecan/cisplatin carries greater hematological toxicity 
but less risk of neuropathic pain. A guiding principle for 
palliative chemotherapy is minimization of symptoms and 
side-effects that worsens a patient’s quality of life. In our 
institution, we favor the FDA approved combination until 
data from GOG-204 are published.
Other combinations of topotecan
A combination of topotecan and paclitaxel for treatment 
of persistent, recurrent or metastatic cervical cancer was 
investigated in a phase II study of 15 patients. The treat-
ment protocol consisted of 175 mg/m2 paclitaxel on day1 
and 1 mg/m2 topotecan on days 1–5 of a 25-day cycle with 
granulocyte colony stimulating factor (GCSF) support and 
the standard pretreatment regimen for paclitaxel. Overall 
response was 54% and progression-free survival 3.7 months 
with a median overall survival of 8.6 months. Grade 3/4 
toxicities included anemia (47%), leukopenia (27%), neuro-
toxicity (13%), thrombocytopenia (13%), and diarrhea (13%) 
(Tiersten et al 2004).
The several combination chemotherapeutic protocols 
have not shown improved response, or had similar response 
with more severe toxicities in most patients than those treated 
by Cisplatin and topotecan combination (see Table 3).
Quality of life (QOL) during 
topotecan treatment
Several studies have investigated the QOL in patients with 
advanced cervical cancer with treatments. Patient-reported 
QOL measures are an important considerations when using 
chemotherapy with non-curative intent. Monk et al (2005) 
examined QOL data in conjunction with the GOG random-
ized phase III trial of cisplatin with or without topotecan. 
They demonstrated no statistically signiﬁ  cant differences 
in QOL up to 9 months after randomization. QOL was 
assessed using Functional Assessment of Cancer Therapy-
General (FACT-G), Cervix subscale (Cx subscle), FACT/
GOG-Neurotoxicity subscale (NTX subscale), Brief Pain 
Inventory(BPI), and UNISCALE (UNI). They concluded that 
despite increased hematological toxicity, cisplatin/topotecan 
did not signiﬁ  cantly reduce the QOL when compared with 
cisplatin alone (p = 0.0016).
Toptecan and radiation
Topotecan has also been examined as a radiosensitizing agent 
due to its ability to both sabotage repair of sublethal cell 
injury and to prevent HIF-regulated hypoxic cell survival. 
Dunton and coworkers (2002) studied the maximal tolerance 
dose (MTD) of topotecan with external beam radiotherapy in 
advanced cervical cancer. They concluded that topotecan can 
be safely administered at a dose of 1 mg/m2 daily for 5 days 
on days 1–5 and 22–26 concomitantly with radiotherapy 
without signiﬁ  cant toxicity. Grade III anemia in one case 
and grade II leukopenia in two cases were seen at this dose 
level. Dose limiting toxicity was not reached.
Bell and associates (2001) published a phase I study 
using topotecan during radiation implant after completion 
of external-beam therapy. He found the maximum tolerated 
dose of 0.5 mg/m2. The data differed by dose and pretreat-
ment with external beam therapy.
Future directions
Several phase II studies have demonstrated topote-
can to be an active agent in cervical cancer. (Table 4) 
Table 1 Hematologic adverse events in patients treated with 
topotecan + cisplatin or cisplatin alone (derived from data of 
Long et al 2005)
Adverse events  Grade  TC 140 patient   C 144 patient
Anemia  3  47 (34%)  28 (19%)
  4  9 (6%)  5 (3%)
Leukopenia  3  58 (41%)  1 (1%)
  4  35 (25%)  0 (0%)
Neutropenia  3  36 (26%)  1 (1%)
  4  67 (48%)  1 (1%)
Thrombocytopenia  3  36 (26%)  5 (3%)
  4  10 (2%)  0 (0%)
Abbreviations: C, cisplatin; TC, topotecan + cisplatin.
Table 2 Non-hematologic adverse events in patients treated 
with TC or C alone (derived from data of Long et al 2005)
Adverse events  TC  C
Gastrointestinal 45%  28%
Pain 22%  16%
Metabolic-Laboratory 14% 10%
Hepatic 5%  1%
Dermatologic 48%  20%
Abbreviations: C, cisplatin; TC, topotecan + cisplatin.Therapeutics and Clinical Risk Management 2008:4(1) 217
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In an effort to ameliorate toxicity noted with 3- to 5-day 
dosing regimens of topotecan, investigators are currently 
recruiting patients in a phase I study for efficacy of 
weekly topotecan with cisplatin in advanced stage or 
recurrent cervical cancer. Topotecan will be given weekly 
at escalating dose levels starting at 2.0 mg/m2 with stan-
dard cisplatin at 50 mg/m2 every 21 days (available at 
www.clinicaltials.gov identifier NCT00322920 ). Also, 
a phase II evaluation of weekly topotecan is currently 
underway in patients with persistent or recurrent carci-
noma of the cervix (available at http://ycctrials.med.yale.
edu/listprotocolsbydisease.asp).
Weekly topotecan in combination with pemetrexed is in a 
phase I trial in patients with advanced malignancies (available 
at www.clinicaltials.gov Identiﬁ  er NCT00315861).
Lastly, the combination of paclitaxel together with 
topotecan and cisplatin in treating patients with advanced, 
persistent, or recurrent cervical cancer is being evaluated in a 
phase II trial (available at www.clinicaltrials.gov ID numbers 
CDR000456248; GOG-0076EE).
In an effort to further improve radiosensitization, phase II 
trials is currently underway studying topotecan and cisplatin 
with radiation in cervical carcinoma (available at www.
clinicaltrials.gov Identiﬁ  er NCT00257816; NCT003220983 
and NCT000287911). It is expected that synergy between the 
drugs due to downregulation of HIF by Topotecan in poorly 
perfused tumors.
Conclusion
Improvements in cervical cancer screening have led to a 
decline in the incidence of cervical cancer, but this diseaese 
is still a leading cause of cancer related mortality worldwide. 
Advances in the treatment of cervical cancer have led to 
the use of chemoradiation in locally advanced disease, but 
few treatment options remain for women with advanced, 
recurrent, or persistent disease. Topotecan and cisplatin 
combination approved by FDA have produced higher 
survival and progression free survival rates in the manage-
ment of these patients. Data from GOG 204 will need to be 
evaluated to determine the effect of survival with combina-
tion therapy. Topotecan is being investigated in its role as a 
chemosensitizer in patients receiving radiotherapy. Ongoing 
studies to ﬁ  nd better combination and dosing regimen with 
less toxicity and more efﬁ  cient therapy are needed to continue 
Table 4 Topotecan in phase II studies for treatment of recurrent cervical carcinoma
Study Treatment history Treatment Number 
of patients
PFS RR OS
Noda et al 1996 76% prior chemotherapy Topotecan 1.2 mg/m2, 5 days 22 NR 18% NR
Abu-Rustam et al 2000 Platinum prior based chemotherapy Topotecan 1 mg/m2/d on days 1–5 of a 
21-day cycwle
12 NR 17% NR
Muderspach et al 2001 No chemotherapy Topotecan 1.5 mg/m2 40 2.1 13% 6.4
Bookman et al 2000 88% prior chemotherapy Topotecan 1.5 mg/m2 40 2.1 13% 6.6
Fiorica et al 2002 No chemotherapy Topotecan 0.75 mg/m2 + cisplatin 50 mg/m2 32 5 28% 10
Tiersten et al 2004 Prior radiotherapy Topotecan 1 mg/m2 + paclitaxel 175 mg/m2 15 3.7 54% 8.62
Abbreviations: NR, not reported; OS, overall survival; PFS, progression-free survival; RR, response rate.
Table 3 Combination regimens in treatment of persistent or recurrent cervical cancer
Author Agent Dose Response
Rate %
Toxicity
Brewer et al 2006 C+gemcitabine 30 mg/m2+800 mg/m2/d 1,8
Q 28 d
22 Hematologic
Mannel et al 2000 C+pentoxifylline 75 mg/m2+1600 mg PO 9 d Q8H q21d 10 N/V 32%, hematologic 23%
Zanetta et al 1999 C+ifosfamide+paclitaxel
(TIP)
75 mg/m2+5 g/m2+175 mg/m2 52 Myelotoxicity 91%
Choi et al 2006 (TIP) 50 mg/m2+1500 mg/m2+135 mg/m2 46.7 Neutropenia 13%- neurotoxicity 5%
Pohlmann et al 2002 C+decitabine 40 mg/m2+50 mg/m2 q21d 38.1 Neutropenia 68%
Maluf et al 2006 C+Tirapazamine 75 mg/m2+330 mg/m2 27.8 Anemia, fatigue, N/V
Serkies et al 2006 C+ifosfamide+mitomycin 50 mg/m2+3 g/m2 q21d 34 Leukopenia 59%
Muggia et al 2004 C+irinotecan 25 mg/m2+65 mg/m2 q21d 16 Myelosuppression+gastrointestinal
Ohwada et al 2004 Irinotecan+nedaplatin 50 mg/m2/d 1,8,15+60 mg/m2/d 1q4wk 40 Leukopenia 40%, neutropenia 38%
Abbreviations: C, cisplatin; TIP, cisplatin + ifosfamide + paclitaxel; N/V, nausea/vomitingTherapeutics and Clinical Risk Management 2008:4(1) 218
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to improve the QOL and survival of patients with persistent 
or recurrent cervical cancer.
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